Rena Conti
@contirena1
Followers
4K
Following
15K
Media
51
Statuses
4K
health economics & policy biopharmaceutical supply, demand, & innovation
United States
Joined February 2016
Attention: PhD students and early-career researchers interested in the fiscal and economic effects of productivity policies -- particularly R&D, immigration, and infrastructure permitting. Apply for this @SloanFoundation @nberpubs fellowship (due 1/4/26):
1
28
85
On exubera, 1. Limited support for benefit/health risks, given outside options; 2. Company leaned on value of convenience/adherence; 3. Data not compelling to support 1 & 2 at launch; 4. Potential Budget impact huge
@contirena1 Great example. Afrezza too. Is there a consensus if the reason for those busts was (1) insurance coverage challenges, or (2) some AEs relative to insulin that make it hard to change, or (3) something else?
0
0
1
new IQVIA report offering up an interesting graph on the refrain that the US is a major outlier in drug spending from a global perspective https://t.co/QceZpSj6MP
3
8
29
BU Questrom is launching a new PhD Program in Business Economics focused on how markets and firms interact with public policy. Graduates will be ready for research and teaching roles in both business schools and econ departments.
7
45
303
Really enjoyed doing this podcast with the @NucleateHQ team! What it Takes to Build a $50B Biotech Moonshot | John Maraganore, Foundi... https://t.co/TvpVvF2pn6 via @YouTube
1
3
19
For readers interested in progress and challenges in developing n-of-1 therapies like the one for baby KJ, here's a review https://t.co/FzizYxjJsc
https://t.co/HtwRVgHPZr and an interview with Rebecca Ahrens https://t.co/g2IyuAGzH3
1
13
37
And his mother started chloe, the fashion brand :)
I also love the fact that somebody looked at this collar situation and said: "Ah well, it's good enough. Let's just roll with it."
0
0
1
Innovation in medicines for global health: a 20-year landscape analysis https://t.co/RoK9wFF3x7 This article analyses progress in the development of drugs for diseases including Ebola, trypanosomiasis, malaria, onchocerciasis, sickle cell disease, thalassaemia and tuberculosis
1
31
80
Yes as Andrew Lo and I have been saying for years, these new therapies require innovative payment models. Push incentives are not enough because $$ is king in investor decisions.
Interesting piece from Lei Lei Wu on Jim Wilson's rethink on gene therapies for ultra-rare diseases. We can cure some awful diseases, but they don't make money. Trying to use the prospect of PRVs as an enticement is a non-starter. Right now, more than ever before, telling a
0
0
2
Donald Trump’s Big Pharma Showdown Ends with a Whimper https://t.co/kgnVDniFbJ Superb reporting by superb @JohnCassidy citing true experts, i.e., @contirena1 & @C_Garthwaite
newyorker.com
Wall Street is celebrating the White House’s deal with Pfizer on drug prices. Patients shouldn’t be.
0
1
1
The link to register for the above panel is here. Scroll down for the 1:30 PM panel
thebiotechclub.org
0
1
4
Job alert: American University is hiring an Assistant Professor in Health Economics. The position is in the departments of economics and health studies... https://t.co/0uvTvueVCo,
0
14
32
Huge @koutterson
For years I have dreamt of a tool that could neutralize pathogens the moment they emerge. Today we unveil ApexOracle—an AI that, from a pathogen’s genome and phenotypic knowledge alone, predicts which antibiotics will work and invents new molecules for threats it has never seen.
1
0
3
We are hiring at Rotman Strategy in the Fall. Apply here.
jobs.utoronto.ca
Assistant Professor - Strategic Management
2
18
31
Just for drugs ultimately approved, but this is still huge. Hope they go back further to 2000s!
Wow... The FDA just posted an archive of Complete Response Letters from 2020-2024 https://t.co/xKwk8w2Opl
0
0
1
Wow!! Would be a huge change. Will it be retrospective or only prospective?
1
1
1
A new Pediatric Center for CRISPR Cures builds on the recent saved life of Baby KJ, who expeditiously had bespoke base genome editing in the body. @Doudna_lab @ChanZuckerberg @UCSFMedicine @UCBerkeley
3
60
241
A $10 increase in buprenorphine cost-sharing was estimated to have no effect on prescription abandonment for commercially insured patients and a slight increase for #Medicare-insured patients. https://t.co/wTQSnnnamE
@contirena1 @poojalagisetty @kaopingchua
0
3
5
New pub @JAMAHealthForum: we estimated the association between cost-sharing and buprenorphine dispensing by exploiting the abrupt increase in cost-sharing at the beginning of the calendar year, when deductibles reset in private and Medicare plans @kaopingchua @contirena1
2
4
12
Guido 👏👏👏👏👏Thank you
On June 30, 2025, Guido Imbens stepped down as Editor. We express our immense gratitude for his six years of exceptional service and leadership.
0
0
1